MacroGenics | MGNX - Net Income


MacroGenics reported $-36.77M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
AbbVie USD 3.61B 2.92B Jun/2026
Amgen USD 2.38B 556M Jun/2026
AstraZeneca USD 2.51B 573M Jun/2026
Biogen USD 97.5M 222M Jun/2026
Bristol-Myers Squibb USD 3.32B 640M Jun/2026
Daiichi Sankyo JPY 68.64B 18B Jun/2026
Eli Lilly USD 7.1B 301M Jun/2026
Genmab DKK 303M 250M Jun/2026
Geron USD -3.64M 27.5M Mar/2026
Gilead Sciences USD -10.5B 12.52B Jun/2026
J&J USD 5.53B 299M Jun/2026
Karyopharm Therapeutics USD -22.39M 79.81M Mar/2026
MacroGenics USD -36.77M 22.62M Mar/2026
Merck USD -1.34B 2.9B Jun/2026
Pfizer USD -248M 2.94B Jun/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Xencor USD -21.73M 107.19M Jun/2026